Sodium glucose co‐transporter 2 inhibitors (SGLT2is) are the first class of glucose lowering
agent to be shown to reduce cardiovascular events. They are generally well tolerated with …

Abstract Sodium-glucose co-transporter 2 (SGLT2) inhibitors have a well-defined safety
profile based on data obtained from numerous clinical trials, including cardiovascular …

Background: Multiple published quantitative systematic reviews have reported on adverse
events associated with the use of sodium glucose co-transporter 2 (SGLT-2) inhibitors in …

Abstract Sodium–glucose cotransporter 2 (SGLT2) inhibitors belong to a novel class of
glucose-lowering medications that reduce plasma glucose concentrations by inhibiting …

Amputation has been known to be a rare adverse event of sodium glucose co-transporter-2
(SGLT2) inhibitors. It remains unclear whether the SGLT2 inhibitor as a class or specific …

Abstract Sodium-glucose co-transporter-2 inhibitors (SGLT2i) are oral antidiabetic agents
that exert their glucose-lowering effect by increasing renal excretion of glucose. These drugs …

Inhibitors of sodium–glucose co-transporter type 2 (SGLT2) are proposed as a novel
approach for the management of type 2 diabetes mellitus (T2DM). Several compounds are …

Introduction: The safety profile of sodium-glucose cotransporter 2 (SGLT2) inhibitors has
continued to evolve with the availability of data from clinical trial programs, post-marketing …

Sodium–glucose linked transporter type 2 (SGLT2) inhibitors are a relatively new class of
antidiabetic drugs with positive cardiovascular and kidney effects. The aim of this review is to …

Background: Sodium glucose co-transport 2 inhibitors (SGLT2-i) are the new class of
antidiabetic medications which are recently approved (2013) by the Food and Drug …